US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NeOnc Technologies Holdings

3.78

+0.10002.72%

Post-market: 3.820.0440+1.16%19:30 EDT

Volume:290.51K

Turnover:1.12M

Market Cap:108.88M

PE:-1.77

High:4.00

Open:3.82

Low:3.69

Close:3.68

52wk High:12.99

52wk Low:3.01

Shares:28.81M

Float Shares:12.03M

Volume Ratio:1.27

T/O Rate:2.42%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1361

EPS(LYR):-3.2036

ROE:--

ROA:-634.99%

PB:-5.03

PE(LYR):-1.18

Loading ...

Overview Company News Filings

Press Release: NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a Neo100 Data Readout

NeOnc Technologies Hosts Call on Phase 2a Topline Data for Intranasal Neo100 in Recurrent IDH1-Mutant Glioma

NeOnc Technologies Appoints Accenture Strategy Executive Nasim Shomali to Board

Neonc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors

THOMSON REUTERS

Press Release: NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors

Neonc Gets FDA Written Feedback Backing Neo212 CMC Plan, Flags Bioavailability Study for Tablet Switch

Neonc Technologies - FDA Finds Neonc's Cmc Development Approach Reasonable with Conditions on Manufacturing Changes

THOMSON REUTERS

Neonc Receives FDA Written Feedback on Neo212 Cmc Development and Capsule-to-tablet Transition

THOMSON REUTERS

Neonc Technologies - Cancels July 9 FDA Meeting After Sufficient Written Responses

THOMSON REUTERS

Neonc Technologies - to Update Neo212 Development Plan After Incorporating FDA Feedback

THOMSON REUTERS

Bullish NeOnc Technologies Holdings Insider Buying Worth US$615.6k Yet To Pay Off

Simply Wall St.

Neonc Technologies Director Nasim Shomali Files Initial Beneficial Ownership Statement

Neonc Technologies Names Nasim Shomali to Board After Chiang Resignation

Neonc Wins UAE IND Authorization for Neo100 in Recurrent High-grade Glioma

NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

Neonc Technologies Receives UAE Ind Approval for Neo100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

THOMSON REUTERS

Neonc Technologies - Top-Line Data From Neo100-01 Phase 2a Trial Expected by End of July 2026

THOMSON REUTERS

NeOnc says Abu Dhabi health regulator grants IND status for NEO100 glioma trials

NeOnc gains Abu Dhabi IND clearance for brain cancer drug candidate NEO212

NeOnc Technologies Says Abu Dhabi Clears NEO212 for Phase 2 Brain Cancer Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/NTHI/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NTHI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":3.78,"timestamp":1789416000000,"preClose":3.68,"halted":0,"volume":290506,"hourTrading":{"tag":"盘后","latestPrice":3.824,"preClose":3.78,"latestTime":"19:30 EDT","volume":584,"amount":2218.974,"timestamp":1789428600678,"change":0.044,"changeRate":0.01164,"amplitude":0.01164},"delay":0,"changeRate":0.027173913043478163,"floatShares":12025000,"shares":28805400,"eps":-2.136127,"marketStatus":"Closed","change":0.1,"latestTime":"09-14 16:00:00 EDT","open":3.82,"high":4,"low":3.685,"amount":1122067.2818492,"amplitude":0.085598,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.136127,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":3.68,"preHourTrading":{"tag":"盘前","latestPrice":3.82,"preClose":3.68,"latestTime":"09:29 EDT","volume":5536,"amount":21138.3889216,"timestamp":1789392541008,"change":0.14,"changeRate":0.038043,"amplitude":0.010788},"postHourTrading":{"tag":"盘后","latestPrice":3.824,"preClose":3.78,"latestTime":"19:30 EDT","volume":584,"amount":2218.974,"timestamp":1789428600678,"change":0.044,"changeRate":0.01164,"amplitude":0.01164},"volumeRatio":1.274585},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","floatShares":12025000,"roa":"-634.99%","roe":"--","lyrEps":-3.203615,"volumeRatio":1.274585,"shares":28805400,"dividePrice":0,"high":4,"amplitude":0.085598,"preClose":3.68,"low":3.685,"week52Low":3.005,"pbRate":"-5.03","psRate":"2722.79","week52High":12.99,"institutionHeld":0,"latestPrice":3.78,"eps":-2.136127,"divideRate":0,"volume":290506,"delay":0,"ttmEps":-2.136127,"open":3.82,"prevYearClose":8.27,"prevWeekClose":3.68,"prevMonthClose":4.94,"prevQuarterClose":4.53,"fiveDayClose":5.03,"twentyDayClose":4.22,"sixtyDayClose":4.81},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTHI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"NTHI","fiscalQuarterEnding":"2026/06","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2026-05-15","symbol":"NTHI","fiscalQuarterEnding":"2026/03","expectedEps":-0.3,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.38},{"market":"US","date":"2026-03-31","symbol":"NTHI","fiscalQuarterEnding":"2025/12","expectedEps":-0.37,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-14","symbol":"NTHI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-18","symbol":"NTHI","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1755489600000,"reportTimeType":"","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTHI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NTHI\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1779422400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NTHI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NTHI","date":"2026-09-11","current":-1.769558,"percent":0.920765,"low":-26.074295,"twenty":-4.158229,"median":-3.040027,"eighty":-2.239017,"high":-1.357276,"avg":-3.95466,"sd":3.229626,"marketCap":90975968},"quantilePoints":[{"date":"2024-03-28","current":-18.899455,"twenty":-18.899455,"median":-18.899455,"eighty":-18.899455,"marketCap":282000000},{"date":"2025-03-28","current":-18.905834,"twenty":-19.009816,"median":-18.905834,"eighty":-18.902007,"marketCap":224950380},{"date":"2025-04-04","current":-15.093157,"twenty":-20.260752,"median":-18.902645,"eighty":-16.151884,"marketCap":179585386},{"date":"2025-04-11","current":-14.179375,"twenty":-19.504518,"median":-17.739974,"eighty":-15.124667,"marketCap":168712785},{"date":"2025-04-17","current":-11.028403,"twenty":-19.044476,"median":-15.392499,"eighty":-12.855967,"marketCap":131221055},{"date":"2025-04-25","current":-9.437162,"twenty":-18.904558,"median":-14.667776,"eighty":-10.965384,"marketCap":112287731},{"date":"2025-05-02","current":-8.444606,"twenty":-18.667559,"median":-12.525115,"eighty":-9.437162,"marketCap":100477836},{"date":"2025-05-09","current":-10.398208,"twenty":-17.342951,"median":-11.028403,"eighty":-9.33318,"marketCap":123722709},{"date":"2025-05-16","current":-2.933338,"twenty":-15.682389,"median":-10.398208,"eighty":-8.444606,"marketCap":137753858},{"date":"2025-05-23","current":-2.969802,"twenty":-15.348385,"median":-9.44504,"eighty":-3.015179,"marketCap":139466268},{"date":"2025-05-30","current":-2.99006,"twenty":-15.171931,"median":-9.437162,"eighty":-2.969802,"marketCap":140417606},{"date":"2025-06-06","current":-3.034627,"twenty":-15.093157,"median":-9.311123,"eighty":-2.969802,"marketCap":142510552},{"date":"2025-06-13","current":-2.593006,"twenty":-14.242395,"median":-8.476116,"eighty":-2.937389,"marketCap":121771366},{"date":"2025-06-20","current":-1.928548,"twenty":-14.191979,"median":-7.853798,"eighty":-2.929004,"marketCap":90567453},{"date":"2025-06-27","current":-1.616577,"twenty":-12.855967,"median":-3.034627,"eighty":-2.802066,"marketCap":75916836},{"date":"2025-07-03","current":-2.362066,"twenty":-12.222621,"median":-3.010317,"eighty":-2.532985,"marketCap":110926104},{"date":"2025-07-11","current":-1.977167,"twenty":-11.425425,"median":-2.998163,"eighty":-2.362066,"marketCap":92850666},{"date":"2025-07-18","current":-1.786743,"twenty":-11.028403,"median":-2.99006,"eighty":-2.222692,"marketCap":83908082},{"date":"2025-07-25","current":-1.904238,"twenty":-10.981139,"median":-2.959854,"eighty":-1.949616,"marketCap":89425847},{"date":"2025-08-01","current":-1.98527,"twenty":-10.618776,"median":-2.937389,"eighty":-1.970684,"marketCap":93231202},{"date":"2025-08-08","current":-1.944754,"twenty":-10.133526,"median":-2.931642,"eighty":-1.939892,"marketCap":91328524},{"date":"2025-08-15","current":-2.102765,"twenty":-9.654579,"median":-2.909028,"eighty":-1.943134,"marketCap":98748967},{"date":"2025-08-22","current":-2.604584,"twenty":-9.443464,"median":-2.799635,"eighty":-1.954478,"marketCap":110548110},{"date":"2025-08-29","current":-3.15078,"twenty":-9.437162,"median":-2.795584,"eighty":-1.970684,"marketCap":133730643},{"date":"2025-09-05","current":-3.371966,"twenty":-9.437162,"median":-2.876616,"eighty":-1.980408,"marketCap":143118611},{"date":"2025-09-12","current":-4.405675,"twenty":-9.43086,"median":-2.918386,"eighty":-1.98527,"marketCap":186992991},{"date":"2025-09-19","current":-5.457439,"twenty":-9.377293,"median":-2.933338,"eighty":-1.993373,"marketCap":231633736},{"date":"2025-09-26","current":-4.681029,"twenty":-9.292217,"median":-2.939656,"eighty":-2.005528,"marketCap":198680053},{"date":"2025-10-03","current":-5.141458,"twenty":-8.961365,"median":-2.969802,"eighty":-2.008769,"marketCap":218222354},{"date":"2025-10-10","current":-5.407785,"twenty":-8.482417,"median":-2.99006,"eighty":-2.016872,"marketCap":229526233},{"date":"2025-10-17","current":-4.730683,"twenty":-8.444606,"median":-3.002214,"eighty":-2.039561,"marketCap":200787556},{"date":"2025-10-24","current":-3.769199,"twenty":-7.97196,"median":-3.022472,"eighty":-2.067922,"marketCap":159978635},{"date":"2025-10-31","current":-4.590749,"twenty":-7.105442,"median":-3.15078,"eighty":-2.071973,"marketCap":194848230},{"date":"2025-11-07","current":-4.446301,"twenty":-6.304447,"median":-3.298614,"eighty":-2.085748,"marketCap":188717312},{"date":"2025-11-14","current":-4.053582,"twenty":-5.457439,"median":-3.638293,"eighty":-2.120592,"marketCap":172048879},{"date":"2025-11-21","current":-2.32457,"twenty":-5.457439,"median":-3.482559,"eighty":-2.150574,"marketCap":113613569},{"date":"2025-11-28","current":-3.566132,"twenty":-5.449314,"median":-3.447134,"eighty":-2.162729,"marketCap":174295011},{"date":"2025-12-05","current":-3.725512,"twenty":-5.41591,"median":-3.522302,"eighty":-2.193521,"marketCap":182084733},{"date":"2025-12-12","current":-3.733481,"twenty":-5.411396,"median":-3.568124,"eighty":-2.214589,"marketCap":182474219},{"date":"2025-12-19","current":-2.797122,"twenty":-5.405979,"median":-3.570116,"eighty":-2.278603,"marketCap":136709607},{"date":"2025-12-26","current":-3.327062,"twenty":-5.398757,"median":-3.566132,"eighty":-2.301292,"marketCap":162610430},{"date":"2026-01-02","current":-3.295186,"twenty":-5.391535,"median":-3.474488,"eighty":-2.319914,"marketCap":161052485},{"date":"2026-01-09","current":-3.916768,"twenty":-5.368062,"median":-3.548202,"eighty":-2.33285,"marketCap":191432398},{"date":"2026-01-16","current":-3.466519,"twenty":-5.344589,"median":-3.566132,"eighty":-2.344813,"marketCap":169426436},{"date":"2026-01-23","current":-3.486442,"twenty":-5.296741,"median":-3.53824,"eighty":-2.348861,"marketCap":170400151},{"date":"2026-01-30","current":-3.486442,"twenty":-5.229933,"median":-3.552186,"eighty":-2.357204,"marketCap":170400151},{"date":"2026-02-06","current":-3.681683,"twenty":-5.174862,"median":-3.566132,"eighty":-2.362066,"marketCap":179942559},{"date":"2026-02-13","current":-4.169784,"twenty":-5.146875,"median":-3.570116,"eighty":-2.389761,"marketCap":203798580},{"date":"2026-02-20","current":-3.426674,"twenty":-5.12611,"median":-3.574101,"eighty":-2.410019,"marketCap":167479005},{"date":"2026-02-27","current":-4.020365,"twenty":-5.049824,"median":-3.613946,"eighty":-2.417236,"marketCap":196495717},{"date":"2026-03-06","current":-3.835101,"twenty":-4.966315,"median":-3.638073,"eighty":-2.428412,"marketCap":187440892},{"date":"2026-03-13","current":-3.660224,"twenty":-4.933814,"median":-3.653791,"eighty":-2.438178,"marketCap":178893747},{"date":"2026-03-20","current":-3.253532,"twenty":-4.851659,"median":-3.642057,"eighty":-2.502974,"marketCap":159016664},{"date":"2026-03-27","current":-2.981402,"twenty":-4.767698,"median":-3.621915,"eighty":-2.597637,"marketCap":145716276},{"date":"2026-04-02","current":-1.961459,"twenty":-4.735197,"median":-3.603287,"eighty":-2.595322,"marketCap":121897269},{"date":"2026-04-10","current":-1.961307,"twenty":-4.734294,"median":-3.574101,"eighty":-2.414974,"marketCap":121887825},{"date":"2026-04-17","current":-2.012281,"twenty":-4.720752,"median":-3.566132,"eighty":-2.352342,"marketCap":125055639},{"date":"2026-04-24","current":-1.920085,"twenty":-4.679223,"median":-3.562148,"eighty":-2.305948,"marketCap":119325998},{"date":"2026-05-01","current":-1.771769,"twenty":-4.657556,"median":-3.53824,"eighty":-2.205893,"marketCap":110108750},{"date":"2026-05-08","current":-2.630543,"twenty":-4.597971,"median":-3.502161,"eighty":-2.162729,"marketCap":163478290},{"date":"2026-05-15","current":-2.213061,"twenty":-4.588041,"median":-3.478473,"eighty":-2.19289,"marketCap":137533354},{"date":"2026-05-22","current":-3.511755,"twenty":-4.577207,"median":-3.486442,"eighty":-2.19724,"marketCap":135694649},{"date":"2026-05-29","current":-3.138303,"twenty":-4.577207,"median":-3.483777,"eighty":-2.19881,"marketCap":121264435},{"date":"2026-06-05","current":-2.990888,"twenty":-4.568179,"median":-3.474488,"eighty":-2.200003,"marketCap":115568297},{"date":"2026-06-12","current":-2.948302,"twenty":-4.559151,"median":-3.434643,"eighty":-2.209008,"marketCap":113922747},{"date":"2026-06-18","current":-3.151407,"twenty":-4.512205,"median":-3.406752,"eighty":-2.21225,"marketCap":121770758},{"date":"2026-06-26","current":-2.954853,"twenty":-4.486024,"median":-3.393823,"eighty":-2.226031,"marketCap":114175908},{"date":"2026-07-02","current":-2.922095,"twenty":-4.474288,"median":-3.367616,"eighty":-2.229383,"marketCap":112910100},{"date":"2026-07-10","current":-3.013469,"twenty":-4.460746,"median":-3.339093,"eighty":-2.231778,"marketCap":116440808},{"date":"2026-07-17","current":-2.181241,"twenty":-4.449912,"median":-3.327062,"eighty":-2.231778,"marketCap":84283436},{"date":"2026-07-24","current":-2.436279,"twenty":-4.432759,"median":-3.283232,"eighty":-2.231778,"marketCap":94138114},{"date":"2026-07-31","current":-2.342317,"twenty":-4.416509,"median":-3.25181,"eighty":-2.244708,"marketCap":90507443},{"date":"2026-08-07","current":-2.349029,"twenty":-4.389966,"median":-3.211511,"eighty":-2.26624,"marketCap":90766777},{"date":"2026-08-14","current":-1.763689,"twenty":-4.333179,"median":-3.181853,"eighty":-2.231004,"marketCap":83246101},{"date":"2026-08-21","current":-2.401422,"twenty":-4.279913,"median":-3.15078,"eighty":-2.244708,"marketCap":113347108},{"date":"2026-08-28","current":-2.42512,"twenty":-4.273416,"median":-3.115982,"eighty":-2.26624,"marketCap":114465665},{"date":"2026-09-04","current":-2.522546,"twenty":-4.230747,"median":-3.083785,"eighty":-2.27546,"marketCap":119064177},{"date":"2026-09-11","current":-1.927457,"twenty":-4.158229,"median":-3.040027,"eighty":-2.239017,"marketCap":90975968}],"updateTime":1789434605081},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTHI\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658939707","title":"Press Release: NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a Neo100 Data Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939707","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939707?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:00","pubTimestamp":1786366800,"startTime":"0","endTime":"0","summary":"for NEO100, covering all three NEO100 programs across adult Phase 1. through Phase 2, as well as pediatric studies. The authorization extends. NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S.development, where NEO100 holds FDA Orphan Drug, Fast Track and Rare. -- NEO212 UAE IND Approval: Also in June, the Company secured UAE IND. approval for NEO212, enabling Phase 2 evaluation of the Company's oral. perillyl alcohol-temozolomide conjugate in the United Arab Emirates. The","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007","BK4555","BK4604","BK4099","BK4585","TM","BK4588","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658360489","title":"NeOnc Technologies Hosts Call on Phase 2a Topline Data for Intranasal Neo100 in Recurrent IDH1-Mutant Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658360489","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658360489?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:31","pubTimestamp":1786365104,"startTime":"0","endTime":"0","summary":"NeOnc Technologies hosts call on Phase 2a topline data for intranasal NEO100 in recurrent IDH1-mutant gliomaNeOnc Technologies scheduled an Aug. 12, 2026 investor call to present topline Phase 2a resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL9fbgfd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BN0W2V16.EUR","NDAQ","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","BCDF","NTHI","IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","SG9999014039.USD","LU0314104364.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048177","title":"NeOnc Technologies Appoints Accenture Strategy Executive Nasim Shomali to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048177","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048177?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:02","pubTimestamp":1785157342,"startTime":"0","endTime":"0","summary":"NeOnc Technologies appoints Accenture strategy executive Nasim Shomali to boardNeOnc Technologies named strategy and finance executive Nasim Shomali to its board, effective July 1, 2026.Shomali most r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL96tSV3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149725797.USD","SG9999014021.USD","LU2133065610.SGD","LU1228905540.USD","LU1032466523.USD","LU1506573853.SGD","LU2247934214.USD","IE00BN0W2W23.USD","LU0342679015.USD","LU0545562505.USD","LU0265550359.USD","LU0868494708.USD","BK4561","LU2210149790.SGD","LU0661504455.SGD","LU2211815571.USD","BK4566","IE00BSNM7G36.USD","SG9999014898.SGD","NDAQ","BK4534","LU0081259029.USD","LU0265550946.USD","LU1585245621.USD","BCDF","IE00B3QW5Z07.USD","IE00BHPRN162.USD","IE00BFSS7M15.SGD","LU0175139822.USD","SG9999018865.SGD","IE00BJJMRY28.SGD","NTHI","LU0157215616.USD","IE00BJJMRX11.SGD","IE00BN0W2V16.EUR","LU0511384066.AUD","LU1116320737.USD","LU0323239441.USD","IE00BKPKM429.USD","LU1366333091.USD","IE00B64PRP62.GBP","LU0289960550.SGD","SG9999014880.SGD","LU0314104364.USD","LU1235294995.USD","LU1046421795.USD","IE00B7KXQ091.USD","ACN","SG9999017495.SGD","IE00BFSS8Q28.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048675","title":"Neonc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048675","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048675?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA7MQYKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048668","title":"Press Release: NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048668","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048668?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:00","pubTimestamp":1785157200,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (\"NeOnc\" or the \"Company\"), a multi-Phase 2 clinical-stage biopharmaceutical company developing no","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4232","CNS","R","03160","BK4585","BK4135","BK4588","BK4604","IND","NTHI","TM","BK4555","BK4099","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651651714","title":"Neonc Gets FDA Written Feedback Backing Neo212 CMC Plan, Flags Bioavailability Study for Tablet Switch","url":"https://stock-news.laohu8.com/highlight/detail?id=2651651714","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651651714?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:03","pubTimestamp":1784120621,"startTime":"0","endTime":"0","summary":"NeOnc gets FDA written feedback backing NEO212 CMC plan, flags bioavailability study for tablet switchNeOnc received FDA written feedback on CMC plans for NEO212, supporting continued development and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL6NHtNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NDAQ","BCDF","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4112","BK4588","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014039.USD","NTHI","IE00B3QW5Z07.USD","BK4007","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651465990","title":"Neonc Technologies - FDA Finds Neonc's Cmc Development Approach Reasonable with Conditions on Manufacturing Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2651465990","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651465990?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:00","pubTimestamp":1784120408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA1YSGFZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651465921","title":"Neonc Receives FDA Written Feedback on Neo212 Cmc Development and Capsule-to-tablet Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2651465921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651465921?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:00","pubTimestamp":1784120408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA1YSGFZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651465906","title":"Neonc Technologies - Cancels July 9 FDA Meeting After Sufficient Written Responses","url":"https://stock-news.laohu8.com/highlight/detail?id=2651465906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651465906?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:00","pubTimestamp":1784120408,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA1YSGFZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651465185","title":"Neonc Technologies - to Update Neo212 Development Plan After Incorporating FDA Feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=2651465185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651465185?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:00","pubTimestamp":1784120408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA1YSGFZ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651577184","title":"Bullish NeOnc Technologies Holdings Insider Buying Worth US$615.6k Yet To Pay Off","url":"https://stock-news.laohu8.com/highlight/detail?id=2651577184","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651577184?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:51","pubTimestamp":1784112694,"startTime":"0","endTime":"0","summary":"The recent price decline of 15% in NeOnc Technologies Holdings, Inc.'s ( NASDAQ:NTHI ) stock may have disappointed...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nthi/neonc-technologies-holdings/news/bullish-neonc-technologies-holdings-insider-buying-worth-us6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nthi/neonc-technologies-holdings/news/bullish-neonc-technologies-holdings-insider-buying-worth-us6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651144107","title":"Neonc Technologies Director Nasim Shomali Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2651144107","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651144107?lang=en_us&edition=fundamental","pubTime":"2026-07-14 05:00","pubTimestamp":1783976448,"startTime":"0","endTime":"0","summary":"Neonc Technologies director Nasim Shomali files initial beneficial ownership statementNeonc Technologies Holdings director Nasim Shomali reported 160 shares of common stock in an initial Form 3 filing","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL7Dc88W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648463516","title":"Neonc Technologies Names Nasim Shomali to Board After Chiang Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2648463516","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648463516?lang=en_us&edition=fundamental","pubTime":"2026-07-03 05:12","pubTimestamp":1783026765,"startTime":"0","endTime":"0","summary":"NeOnc Technologies names Nasim Shomali to board after Chiang resignationNeOnc Technologies Holdings named Nasim Shomali to its board on July 1, 2026, filling a Class II director seat through the 2027 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL7Sk4LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2247934214.USD","LU0265550946.USD","BK4134","LU1366333091.USD","BK4585","LU1235294995.USD","SG9999014898.SGD","SG9999014906.USD","LU1823568750.SGD","LU1116320737.USD","LU1116320901.HKD","SG9999018857.SGD","BK4588","LU1430594728.SGD","IE000M9KFDE8.USD","BK4581","LU0545039389.USD","LU1228905540.USD","LU1506573853.SGD","SG9999017495.SGD","BK4561","LU1032466523.USD","LU0323240290.USD","LU0323239441.USD","BK4534","IE00BJJMRX11.SGD","NTHI","BK4533","LU0289960550.SGD","LU0545562505.USD","SGXZ23171101.USD","SG9999014914.USD","ACN","LU0868494708.USD","IE00BSNM7G36.USD","IE00B7KXQ091.USD","IE00BHPRN162.USD","LU0511384066.AUD","LU1046421795.USD","LU1989772923.USD","SG9999014880.SGD","SG9999004303.SGD","LU0265550359.USD","LU1228905037.USD","LU2133065610.SGD","LU2211815571.USD","LU0157215616.USD","LU0738911758.USD","LU0661504455.SGD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645813583","title":"Neonc Wins UAE IND Authorization for Neo100 in Recurrent High-grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2645813583","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645813583?lang=en_us&edition=fundamental","pubTime":"2026-06-24 20:45","pubTimestamp":1782305119,"startTime":"0","endTime":"0","summary":"NeOnc wins UAE IND authorization for NEO100 in recurrent high-grade gliomaNeOnc Technologies secured a second UAE Investigational New Drug authorization for NEO100, its intranasal therapy candidate fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL3qkvnC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4585","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","NDAQ","BK4588","BK4007","SG9999014013.SGD","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","NTHI","BK4112","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645813606","title":"NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2645813606","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645813606?lang=en_us&edition=fundamental","pubTime":"2026-06-24 20:45","pubTimestamp":1782305100,"startTime":"0","endTime":"0","summary":"NTHI Continues to Build Regulatory Momentum prior to Upcoming Phase 2 DataDENVER, June  24, 2026  (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is entering one ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/24/3316856/0/en/NeOnc-Ignites-Explosive-Summer-4-New-Research-Reports-UAE-Dubai-Drug-Approval-Fuel-Breakout-Momentum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","NTHI","UAE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839477","title":"Neonc Technologies Receives UAE Ind Approval for Neo100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839477?lang=en_us&edition=fundamental","pubTime":"2026-06-23 21:01","pubTimestamp":1782219713,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839298","title":"Neonc Technologies - Top-Line Data From Neo100-01 Phase 2a Trial Expected by End of July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839298?lang=en_us&edition=fundamental","pubTime":"2026-06-23 21:01","pubTimestamp":1782219713,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0XF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839231","title":"NeOnc says Abu Dhabi health regulator grants IND status for NEO100 glioma trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839231","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839231?lang=en_us&edition=fundamental","pubTime":"2026-06-23 21:01","pubTimestamp":1782219673,"startTime":"0","endTime":"0","summary":"NeOnc Technologies won UAE IND clearance from Abu Dhabi’s Department of Health for NEO100 in recurrent Grade III-IV gliomas.Authorization supports adult trials through Phase 2, with a pediatric pathway under further protocol review.Top-line data from the fully enrolled NEO100-01 Phase 2a study are expected by end-July 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL1Lx44s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU2095319765.USD","BK4588","SG9999014039.USD","LU2210150020.SGD","NDAQ","NTHI","LU2210149790.SGD","BK4112","SG9999014005.SGD","BK4585","IE00BKPKM429.USD","LU0314104364.USD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4007","IE00BGHQF748.EUR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022729","title":"NeOnc gains Abu Dhabi IND clearance for brain cancer drug candidate NEO212","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022729","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022729?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:46","pubTimestamp":1782132404,"startTime":"0","endTime":"0","summary":"NeOnc Technologies secured Department of Health – Abu Dhabi IND authorization for NEO212, opening an additional clinical development pathway for glioblastoma.The oral perillyl alcohol–temozolomide conjugate has completed Phase 1 dose escalation; 610 mg was selected as the recommended Phase 2 dose.The company plans a Type B end-of-Phase 1 meeting with the FDA to discuss next steps and potential registrational pathways.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL64VKM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643768937","title":"NeOnc Technologies Says Abu Dhabi Clears NEO212 for Phase 2 Brain Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643768937","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643768937?lang=en_us&edition=fundamental","pubTime":"2026-06-16 21:52","pubTimestamp":1781617928,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  said Tuesday it has received investigational new drug clearance from the Abu Dhabi's Department of Health for its brain tumor treatment NEO212, enabling phase 2 evaluation of the therapy in the UAE.The authorization marks the first international regulatory clearance for NEO212 following completion of phase 1 clinical evaluation and represents a \"significant step\" toward expanding the program into multiple global markets, the company said.The clearance also adds an international clinical pathway for NEO212 while discussions continue with the US Food and Drug Administration on a potential registrational pathway for the therapy, the company said.Shares of NeOnc Technologies were 6% higher in Tuesday trading.Price: 4.39, Change: -0.12, Percent Change: -2.66","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NTHI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":107,"code":"91000000","status":"200"}]}}